These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 36826353)
1. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital. Pannier J; Nass N; Yaakoub MK; Stelzner FMM; Veit S; Kalomoiri M; Yassine M; Behre G Infect Dis Rep; 2023 Feb; 15(1):125-131. PubMed ID: 36826353 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343 [TBL] [Abstract][Full Text] [Related]
3. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337 [TBL] [Abstract][Full Text] [Related]
6. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987 [TBL] [Abstract][Full Text] [Related]
7. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E Elife; 2022 Nov; 11():. PubMed ID: 36413383 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab. Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138 [TBL] [Abstract][Full Text] [Related]
15. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study. Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124 [TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study. Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398 [TBL] [Abstract][Full Text] [Related]
17. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701 [TBL] [Abstract][Full Text] [Related]
18. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY PeerJ; 2023; 11():e15344. PubMed ID: 37180576 [TBL] [Abstract][Full Text] [Related]
19. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468 [TBL] [Abstract][Full Text] [Related]
20. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]